Page 1 | Search Results | Clinical Cancer Research | American Association for Cancer Research

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Abstract B027: Combining total cell-free DNA (cfDNA) and circulating tumor (ctDNA) to enhance the clinical sensitivity of ddPCR assays to detect minimal residual disease (MRD) in stage IIIB/C/IV melanoma patients on adjuvant immunotherapy in CheckMate 238

Mahrukh M Syeda, Jennifer M Wiggins, Josephine Alegun, Saim Ali, Soutrik Mandal, Tracy (Hao) Tang, Keyur Desai, Sonia Dolfi, Daniel J Tenney, Paolo A Ascierto, James Larkin, Michele Del Vecchio, Jeffrey S Weber, David Polsky

Clin Cancer Res (2024) 30 (21_Supplement): B027.

https://doi.org/10.1158/1557-3265.LIQBIOP24-B027

Published: 13 November 2024

View article titled, Abstract B027: Combining total cell-free DNA (cfDNA) and circulating tumor (ctDNA) to enhance the clinical sensitivity of ddPCR assays to detect minimal residual disease (MRD) in stage IIIB/C/IV melanoma patients on adjuvant immunotherapy in CheckMate 238

Journal Articles

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238

Clin Cancer Res (2023) 29 (17): 3352–3361.

https://doi.org/10.1158/1078-0432.CCR-22-3145

Published: 01 September 2023

View article titled, Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238

Includes: Supplementary data

Journal Articles

Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial

Mehmet A. Bilen, Brian I. Rini, Martin H. Voss, James Larkin, John B.A.G. Haanen, Laurence Albiges, Lance C. Pagliaro, Eric G. Voog, Elaine T. Lam, Nikolay Kislov, Bradley A. McGregor, Aly-Khan A. Lalani, Bo Huang, Alessandra di Pietro, Stan Krulewicz, Paul B. Robbins, Toni K. Choueiri

Clin Cancer Res (2022) 28 (4): 738–747.

https://doi.org/10.1158/1078-0432.CCR-21-1688

Published: 15 February 2022

View article titled, Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial

Includes: Supplementary data

Journal Articles

5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAF^V600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study

Clin Cancer Res (2021) 27 (19): 5225–5235.

https://doi.org/10.1158/1078-0432.CCR-21-0809

Published: 01 October 2021

View article titled, 5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study

Includes: Supplementary data

Journal Articles

Abstract S03-02: Adaptive immunity to SARS-CoV-2 in cancer patients: The CAPTURE study

Lewis Au, Annika Fendler, Laura Amanda Boos, Fiona Byrnes, Scott Shepherd, Emma Nicholson, Scaheen Kumar, Nadia Yousaf, Katalin Wilkinson, Anthony Swerdlow, Ruth Harvey, George Kassiotis, Robert Wilkinson, James Larkin, Samra Turajlic

Clin Cancer Res (2021) 27 (6_Supplement): S03-02.

https://doi.org/10.1158/1557-3265.COVID-19-21-S03-02

Published: 15 March 2021

View article titled, Abstract S03-02: Adaptive immunity to SARS-CoV-2 in cancer patients: The CAPTURE study

Journal Articles

Abstract PO-091: CAPTURE: Cancer and COVID-19 antiviral immune monitoring study

Annika Fendler, Laurie Boos, Lewis Au, Scott Shepherd, Fiona Byrne, Kim Edmonds, Ellie Carlyle, Lyra Del Rosario, Ben Shum, James Larkin, Lisa Pickering, Andrew Furness, Samra Turajlic

Clin Cancer Res (2020) 26 (18_Supplement): PO-091.

https://doi.org/10.1158/1557-3265.COVID-19-PO-091

Published: 15 September 2020

View article titled, Abstract PO-091: CAPTURE: Cancer and COVID-19 antiviral immune monitoring study

Journal Articles

Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era

Michele Maio, Omid Hamid, James Larkin, Alessia Covre, Maresa Altomonte, Luana Calabrò, Santosh A. Vardhana, Caroline Robert, Ramy Ibrahim, Andrea Anichini, Jedd D. Wolchok, Anna Maria Di Giacomo

Clin Cancer Res (2020) 26 (16): 4201–4205.

https://doi.org/10.1158/1078-0432.CCR-20-1657

Published: 14 August 2020

View article titled, Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era

Journal Articles

Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with BRAF^V600-mutated Metastatic Melanoma

Yibing Yan, Matthew J. Wongchenko, Caroline Robert, James Larkin, Paolo A. Ascierto, Brigitte Dréno, Michele Maio, Claus Garbe, Paul B. Chapman, Jeffrey A. Sosman, Zhen Shi, Hartmut Koeppen, Jessie J. Hsu, Ilsung Chang, Ivor Caro, Isabelle Rooney, Grant A. McArthur, Antoni Ribas

Clin Cancer Res (2019) 25 (11): 3239–3246.

https://doi.org/10.1158/1078-0432.CCR-18-0720

Published: 01 June 2019

View article titled, Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with BRAFV600-mutated Metastatic Melanoma

Includes: Supplementary data

Journal Articles

Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib

Matthew J. Wongchenko, Grant A. McArthur, Brigitte Dréno, James Larkin, Paolo A. Ascierto, Jeffrey Sosman, Luc Andries, Mark Kockx, Stephen D. Hurst, Ivor Caro, Isabelle Rooney, Priti S. Hegde, Luciana Molinero, Huibin Yue, Ilsung Chang, Lukas Amler, Yibing Yan, Antoni Ribas

Clin Cancer Res (2017) 23 (17): 5238–5245.

https://doi.org/10.1158/1078-0432.CCR-17-0172

Published: 31 August 2017

View article titled, Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib

Includes: Supplementary data

Journal Articles

Translational Implications of Tumor Heterogeneity

Mariam Jamal-Hanjani, Sergio A. Quezada, James Larkin, Charles Swanton

Clin Cancer Res (2015) 21 (6): 1258–1266.

https://doi.org/10.1158/1078-0432.CCR-14-1429

Published: 12 March 2015

View article titled, Translational Implications of Tumor Heterogeneity

Journal Articles

Immuno-oncology Combinations: A Review of Clinical Experience and Future Prospects

Scott J. Antonia, James Larkin, Paolo A. Ascierto

Clin Cancer Res (2014) 20 (24): 6258–6268.

https://doi.org/10.1158/1078-0432.CCR-14-1457

Published: 14 December 2014

View article titled, Immuno-oncology Combinations: A Review of Clinical Experience and Future Prospects

Journal Articles

Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS–RAF Mutations

Lisa Zimmer, Fabrice Barlesi, Maria Martinez-Garcia, Veronique Dieras, Jan H.M. Schellens, Jean-Philippe Spano, Mark R. Middleton, Emiliano Calvo, Luiz Paz-Ares, James Larkin, Simon Pacey, Miro Venturi, Françoise Kraeber-Bodéré, Jean J.L. Tessier, Wilfried Ernst Erich Eberhardt, Michel Paques, Ernesto Guarin, Valerie Meresse, Jean-Charles Soria

Clin Cancer Res (2014) 20 (16): 4251–4261.

https://doi.org/10.1158/1078-0432.CCR-14-0341

Published: 13 August 2014

View article titled, Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS–RAF Mutations

Includes: Supplementary data

Journal Articles

Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies

Eleni M. Karapanagiotou, Victoria Roulstone, Katie Twigger, Mercel Ball, MaryAnne Tanay, Chris Nutting, Kate Newbold, Martin E. Gore, James Larkin, Konstantinos N. Syrigos, Matt Coffey, Brad Thompson, Karl Mettinger, Richard G. Vile, Hardev S. Pandha, Geoff D. Hall, Alan A. Melcher, John Chester, Kevin J. Harrington

Clin Cancer Res (2012) 18 (7): 2080–2089.

https://doi.org/10.1158/1078-0432.CCR-11-2181

Published: 01 April 2012

View article titled, Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies

Includes: Supplementary data

Journal Articles

Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma

John M. Kirkwood, Lars Bastholt, Caroline Robert, Jeff Sosman, James Larkin, Peter Hersey, Mark Middleton, Mireille Cantarini, Victoria Zazulina, Karin Kemsley, Reinhard Dummer

Clin Cancer Res (2012) 18 (2): 555–567.

https://doi.org/10.1158/1078-0432.CCR-11-1491

Published: 16 January 2012

View article titled, Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma

Includes: Supplementary data

NARROW

Abstract B027: Combining total cell-free DNA (cfDNA) and circulating tumor (ctDNA) to enhance the clinical sensitivity of ddPCR assays to detect minimal residual disease (MRD) in stage IIIB/C/IV melanoma patients on adjuvant immunotherapy in CheckMate 238

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238

Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial

5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAF^V600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study

Abstract S03-02: Adaptive immunity to SARS-CoV-2 in cancer patients: The CAPTURE study

Abstract PO-091: CAPTURE: Cancer and COVID-19 antiviral immune monitoring study

Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era

Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with BRAF^V600-mutated Metastatic Melanoma

Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib

Translational Implications of Tumor Heterogeneity

Immuno-oncology Combinations: A Review of Clinical Experience and Future Prospects

Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS–RAF Mutations

Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies

Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only